Stem cells hold a great potential for the regeneration of damaged tissues in cardiovascular or musculoskeletal diseases. Unfortunately, problems such as limited availability, control of cell fate, and allograft rejection need to be addressed before therapeutic applications may become feasible. Generation of multipotent progenitors from adult differentiated cells could be a very attractive alternative to the limited in vitro self-renewal of several types of stem cells. In this direction, a recently synthesized unnatural purine, named reversine, has been proposed to induce reversion of adult cells to a multipotent state, which could be then converted into other cell types under appropriate stimuli. Our study suggests that reversine treatment transforms primary murine and human dermal fibroblasts into myogenic-competent cells both in vitro and in vivo. Moreover, this is the first study to demonstrate that plasticity changes arise in primary mouse and human cells following reversine exposure.
Stem cells1, 2 attract an ever-increasing interest for their potential therapeutic use for many diseases, such as type I diabetes, muscular dystrophies, cancer, neurodegenerative, and cardiovascular disorders.3, 4, 5 In contrast with embryonic stem cells (ESCs), that nonetheless raise ethic controversy, the majority of human adult stem cells are difficult to expand in culture to the scale required for possible therapeutic applications without loss of pluripotency. In the past few years, several types of adult stem cells have been isolated from different sources and tested for their capability of rescuing the phenotype of several diseases, including muscular dystrophy. Among these, bone marrow-derived multipotent adult progenitors,6 vessel-associated mesoangioblasts,7 and side population (SP) bone marrow-isolated stem cells8 could be differentiated into myocytes both in vitro and in vivo with moderate efficiency. Unfortunately, some adult stem cells, such as hematopoietic stem cells, have a limited self-renewal ex vivo,9 whereas others, such as neural stem cells, are isolated with difficulty from human tissues. Moreover, cell rejection in heterologous cell therapy has been shown as a primary issue to be solved before stem cell therapy may become feasible. In this context, the possibility of re-programming readily available adult cells into multipotent progenitors10 appears a promising alternative, although technically challenging. Within this scenario, Ding and co-workers, after some preliminary attempts by Schultz group,11, 12 have recently synthesized13 an unnatural 2,6-disubstituted purine, named reversine, that has been speculated to induce mouse myogenic cells C2C12 to regress to multipotent progenitor cells, able to differentiate into osteoblasts and adipocytes under proper stimulation. The potential for applications of these challenging results faces the limitation that C2C12 are an immortal, aneuploid, and tumorigenic cell line. Moreover, C2C12 cells have been shown to spontaneously differentiate into osteoblasts14 and adipocytes15 upon proper hormonal stimulation.16 Prompted by the possible new therapeutic perspective generated by these results, we decided to test reversine on readily accessible primary cells, that is, dermal fibroblasts. These cells are easily expandable in vitro and maintain normal phenotype and, more importantly, genetic stability. This model, if workable, would appear to be more robust and offers higher predictive ability towards in vivo counterparts and their response to compound effects.
Our study was initially directed to evaluate the effect of different doses of reversine on fibroblasts proliferation and expression of their tissue-specific markers. In a successive approach, we cocultured reversine-treated fibroblasts with myogenic C2C12 cells, as a stimulus for differentiation, and evaluated their ability to differentiate into skeletal muscle cells. Then, we analyzed the ability of reversine-treated murine fibroblasts to differentiate in vivo after cell transplantation in mice tibialis anterior (TA) muscle, 24 h after a single injection of cardiotoxin that induces muscle regeneration.17
Effect of reversine on primary fibroblasts
Dermal fibroblasts, isolated from transgenic mice expressing green fluorescent protein (GFP), were grown for 4 days in the presence of 5 μM reversine in growth medium as reported by Ding's group for C2C12 cells.13 This concentration appeared to be optimal in the range studied (0.1–10 μM). Control cells were treated with the same volume of dimethylsulfoxide (DMSO) in which reversine was dissolved. After 4 days of reversine treatment, fibroblasts acquired a drastically different morphology (Figure 1b) compared to control cells (Figure 1a), appearing considerably larger in size (up to nine times compared to control cells), flatter, less contrasted, and more adhesive to the culture plate. Unexpectedly, GFP appeared to be localized in the peri-nuclear area (Figure 1b). After minor cell loss during the first day of reversine treatment (30%), no significant cell death was observed, although growth inhibition was noticed, as confirmed by cell count (Figure 2a), XTT (tetrazolium salt) test18 (58% proliferation reduction compared to control cells, data not shown) decrease of cyclin B expression, observed by reverse transcriptase-polymerase chain reaction (RT-PCR) analysis (Figure 2b). Moreover, cell cycle analysis by flow cytofluorimetry indicated the formation of a tetraploid cell population already after 3 h of treatment, reaching about 90% at the end of the treatment (Figure 2c). Treated fibroblasts shifted from a diploid/mononuclear (2n) to a tetraploid/binuclear (2 × 2n) population, possibly through an aborted cytokinesis (Figure 2d), as previously observed by Schultz's group with reversine analogs,19, 20 and as it occurs in normal rat hepatocytes.21 Nevertheless, no significant cell death was observed, even beyond 8–10 days of treatment, showing that reversine treatment does not cause irreversible damage to cells. No significant changes in the mRNA levels of cyclins A, D, and E, nor of p16, p21, and p27 could be detected by RT-PCR in both control and reversine-treated fibroblasts (data not shown). To assess whether reversine treatment alters the plasticity of fibroblasts, we evaluated the expression of fibroblast-specific marker HSP47.22 Reversine treatment caused a decrease of HSP47, which almost disappeared after 8 days (Figure 2b). Interestingly, upon reversine removal, fibroblasts gradually returned to their original phenotype and proliferation rate after 3 weeks in normal culture medium (Figure 2a), and both cyclin B and HSP47 mRNAs were restored (Figure 2b).
Despite evidence of alteration of differentiation status, that is, loss of HSP47 transcripts and altered phenotype, stem cell markers were not detected following exposure to reversine. Hematopoietic stem cell markers such as CD3423 and CD45,24 satellite cell markers such as PAX3 and PAX7,25 or mesenchymal markers such as CD7326 and CD10526 could not be detected by RT-PCR in treated cells (data not shown).
Coculture experiments with C2C12 cells
Initial attempts to induce myogenic differentiation of primary fibroblasts by serum starvation were unsuccessful (data not shown). Moreover, treatment of fibroblasts with a known epigenetic modulator of plasticity 5-aza-C27, 28, 29 (5–30 μM) after 4-day reversine treatment or simultaneously with reversine did not induce myogenesis (data not shown). However, when reversine-treated fibroblasts were cocultured with murine C2C12 myoblasts in differentiation medium for 8 days, they differentiated into multinucleated myotubes expressing both GFP and myosin heavy chain (MHC) (Figure 3b) with remarkably high efficiency. In fact, starting from an initial ratio of 5 : 1 between C2C12 and treated fibroblasts, we observed the formation of about 35% GFP-positive myotubes (Figure 3b). Under the same coculture conditions, but with untreated fibroblasts, we observed the formation of 0.5–2% GFP-positive myotubes (Figure 3a). Moreover, reversine-treated GFP fibroblasts started to express both MHC and MyoD before fusing with C2C12 into myotubes (Figure 3c–d). To exclude that reversine-treated fibroblasts die after removal of reversine and release GFP which is then taken up by C2C12 cells, we added an homogenate of reversine-treated GFP-murine fibroblasts to differentiating C2C12. As we anticipated, at the end of the differentiation process, we did not observe any GFP-positive myotube (data not shown). Finally, we verified that the phenomenon also occurs at clonal level by subjecting both murine and human fibroblasts at cloning by limiting dilution. In all clones tested, we obtained similar results to those described above (Figure 4a).
Reversine-treated fibroblasts undergo myogenic differentiation independently of cell fusion with myoblasts
To test whether human fibroblasts would also be susceptible to the effect of reversine, we treated them with 5 μM reversine and observed analogous morphology changes to the ones seen with murine fibroblasts (Figure 5a–b). Then, we cocultured reversine-treated human fibroblasts with C2C12 cells. Skeletal muscle differentiation in treated human fibroblasts was revealed by double immunofluorescence with antibodies that recognize MHC and human lamin A/C and by RT-PCR with human-specific oligonucleotides that amplify myogenic gene products. Figure 5d shows two human nuclei (white arrows) incorporated in murine myotubes (from C2C12 cells) expressing sarcomeric myosin in the cytoplasm. Overall, we observed the incorporation of human nuclei inside myotubes with a frequency of 25%. Similar results were observed at clonal level (Figure 4b). RT-PCR analysis, performed with human-specific primers, clearly showed the appearance of the human muscle determination gene MyoD in these cocultures (Figure 5c). To discriminate between cell fusion and myotube-induced myogenic determination, we performed a transwell assay with reversine-treated human fibroblasts and differentiating C2C12 cells. Figure 5e shows that untreated human fibroblasts do not undergo myogenesis (Figure 5e′ and e″) when exposed to the medium derived from differentiated C2C12 myotubes (Figure 5e‴) cultured in the upper chamber. In contrast, reversine-treated human fibroblasts underwent frequent muscle differentiation (35% of total cells in the lower chamber) as revealed by double staining with antibodies against human lamin and MHCs (Figure 5f′ and f″) when exposed to medium derived from C2C12 myotubes (Figure 5f‴) cultured in the upper chamber. Moreover, reversine did not induce cell fusion per se, as human and mouse fibroblasts did not form hybrid cells in coculture, as revealed by mutual exclusion of human lamin and GFP (Figure 5g).
Reversine-treated fibroblasts plasticity: differentiation to osteoblasts and smooth muscle cells
To test the extent of plasticity of reversine-treated fibroblasts, we induced their differentiation to other cell types. After a 4-day reversine treatment, fibroblasts were cultured in osteogenic medium containing 0.1 μM dexamethasone, 50 μg/ml ascorbate-2-phosphate, and 10 mM β-glycerophosphate. After 7 days, alkaline phosphatase (ALP) staining revealed the presence of osteoblasts (purple) in the reversine-treated fibroblasts culture (about 45% stained positive, Figure 6c), whereas untreated fibroblasts were negative to ALP staining (Figure 6a). Moreover, when reversine-treated fibroblasts were cultured in Dulbecco's modified Eagle's medium (DMEM) containing 1% fetal bovine serum (FBS) and transforming growth factor-beta 1 (10 ng/ml) for 5 days, cells differentiated into smooth muscle cells (about 20% of treated cells, Figure 6c), as revealed by immunofluorescence with smooth muscle α-actin (α-SMA) antibody (Figure 6b).
In vivo muscle regeneration
The in vivo myogenic ability of reversine-treated murine fibroblasts was tested by direct injection into cardiotoxin-injured TA muscle of wild-type syngeneic mice. Four weeks after fibroblast injection, control and treated animals were killed and immunofluorescence analysis of TA muscle sections was performed. Remarkably, GFP-positive myofibers were observed in all sections of muscles injected with reversine-treated fibroblasts, at a frequency ranging from 5 to 12% at the injection side (Figure 7b, c and e). Interestingly, GFP accumulated in the center of the fiber, similar to its localization in treated fibroblasts in vitro; the basis of this phenomenon remains to be investigated. On the contrary, no GFP-positive fibers were observed in the contralateral leg first treated with cardiotoxin and then with control fibroblasts (Figure 7a). GFP- and MHC- positive fibers are shown in Figure 7e; a higher magnification of regenerating, GFP-positive, centrally nucleated fibers are shown in Figure 7c. Reversine-treated fibroblasts did not cause any apparent adverse effect in vivo. Moreover, GFP-positive, untreated fibroblasts were exclusively located in the interstitium of muscle fibers and did not contribute to muscle fiber formation (Figure 7a).
Ding and Schultz10 pioneered studies aimed at designing and developing a series of synthetic molecules capable of selectively controlling stem cell fate. Very recently, a synthetic 2,6-disubstituted purine, which they named reversine, was identified from a pool of several thousand molecules of a combinatorial library, and proposed to induce de-differentiation in mouse muscle cells.13 Stimulated by the new perspective generated by this discovery, we tested reversine on an accessible and easily expandable primary cell culture, such as dermal fibroblasts. This approach offers a robust source of cells that could be induced to differentiate into myotubes by coculture with C2C12 myoblasts in differentiation medium. Additionally, this is the first study to evaluate reversine-mediated plasticity changes in primary cells, which confers further support to a potential therapeutic application. Despite the fact that reversine exerts effects on C2C12 myoblasts, this is an immortalized line established in vitro, and therefore its response may not be faithfully predictive of the in vitro and in vivo response of a primary cell.30
Reversine treatment of primary cultures of dermal fibroblasts caused a dramatic change in both cell morphology and proliferation. Cells not only enlarged in their size up to nine times compared to control cells (Figure 1a–b), but they also increased their adhesion to the culture plate, as noted during trypsin detachment. The fibroblast marker HSP47 progressively disappeared after treatment, supporting a possible reversine-induced change in lineage commitment (Figure 2b). However, expression of specific stem cell markers was not observed in treated cells. Moreover, reversine treatment reduced cell proliferation and led to the formation of a tetraploid cell population (Figure 2c–d), which reverted to normal ploidy upon drug withdrawal (Figure 2a). Along this line, Schultz's group already reported that some 2,6,9-trisubstituited purines, analogs to reversine, are strong cyclin-dependent kinase inhibitors and lead to the formation of cells with two distinct nucleated microtubule arrays.20 The biological significance of this effect on the cell cycle, observed even at the lowest active concentrations of reversine, is still unclear. Nevertheless, polyploidy is a normal developmental process that occurs in several cellular systems including plants, insects, and mammals, as in skeletal muscle fibers and megakaryocytes, and is often beneficial to the cell, as it allows an increase in metabolic output, cell mass, and cell size, without the need to devote energy to carry on all aspects of cellular division.31 As a result of the treatment, we observed that reversine-treated fibroblasts remain in a quiescent state until properly triggered. In fact, we could induce myogenic differentiation of treated fibroblasts by coculture with C2C12 in a differentiation medium. Strikingly, reversine-treated fibroblasts differentiated very efficiently into myotubes after 7–8 days of coculture (Figure 3b). This remarkable and unexpected fate change was at least one order of magnitude greater than that observed in all previous reported data even in comparison with different types of ‘bona fide’ stem cells.32, 33, 34 Moreover, during coculturing, reversine-treated fibroblasts expressed striated muscle-specific genes such as those encoding MHC and MyoD, before fusion into multinucleated myotubes (Figure 3c–d). Thus myogenesis can be influenced in primary mononucleated fibroblasts by signals emanating from neighboring cells. As a consequence of the acquired myogenic phenotype, fusion with C2C12 cells occurs. Moreover, transwell culture assays of reversine-treated human fibroblasts and differentiating C2C12 caused myogenic differentiation of fibroblasts (Figure 5f). This result was unexpected as previous attempts to induce differentiation of mouse fibroblasts with medium conditioned by myotubes had proven to be ineffective. This may be due to the short half-life of the active molecules; furthermore, the transwell experiment induced myogenic differentiation in both mouse and human fibroblasts, although the latter were far more responsive than mouse cells. Although the basis of this difference is still unclear, it is promising for future clinical exploitation.
When we cocultured human and murine fibroblasts in the presence of reversine, we did not observe any cell fusion (Figure 5g), further supporting the notion that reversine is not a fusogenic molecule. Importantly, the stimulation of myogenic differentiation of fibroblasts also occurred in vivo, in a cardiotoxin model of skeletal muscle regeneration, indicating that the effect on cellular plasticity is not limited to the tissue culture environment (Figure 7). In fact, 4 weeks after injection of reversine-treated fibroblasts in injured TA muscle, GFP- and MHC-positive fibers were observed in all sections analyzed (Figure 7b, c, and e). On the other hand, no GFP-positive fibers were observed in the contralateral leg treated with normal fibroblasts (Figure 7a), which demonstrates that only reversine-treated fibroblasts acquire the capability of regenerating muscle fibers. Our in vivo experiments showed no noticeable toxicity of reversine-treated fibroblasts (up to 5 μM), although we cannot exclude toxicity at higher concentrations. Furthermore, we observed similar results with reversine-treated human dermal fibroblasts, showing that reversine effects are not restricted to rodent cells and may indeed have a potential clinical application.
In conclusion, our data show that primary murine and human fibroblasts treated with reversine can be induced to differentiate into skeletal muscle at high frequency both in vitro and in vivo. It had been previously shown that fibroblasts from different sources have the ability to differentiate into skeletal muscle, but with a very low frequency, below that of possible therapeutic efficacy. Indeed, even SP cells and mesenchymal stem cells differentiate into skeletal muscle at frequency that are below 1%. Moreover, although some recent negative results have been recently reported using reversine-treated C2C12,35 we confirmed and extended previous findings,13 showing that a substantial fraction of treated fibroblasts could be converted into osteoblasts and smooth muscle cells under appropriate conditions. The mechanism by which reversine exerts its effects on fibroblasts is still unknown. Reversine itself does not activate MyoD or Myf5 in fibroblasts and in fact spontaneous myogenic differentiation of treated cells does not occur. Therefore, we can only speculate that reversine reprograms somatic cells to a state of increased plasticity so that further stimuli, such as cell–cell interactions may activate differentiation at high frequency. Further work is necessary to elucidate the mechanism of action of this molecule and to further exploit its potential for cell therapy approaches. In addition, genes subject to reversine treatment in fibroblasts may be identified and become an important tool to activate myogenic competence in these cells, independently of exposure to the molecule itself. The reversible changes on fibroblast-specific transcripts and morphology are similar to those reported following treatment with epigenetic modulators of plasticity, such as 5-aza-C and trichostatin-A.27, 28, 29 Epigenetic mechanisms exert a prominent role during differentiation and cell fate decisions.36 However, we observed that exposure to 5-aza-C along with reversine failed to enhance reversine-related plasticity changes. Therefore, whether reversine effects involve epigenetic changes, as demonstrated in other critical cellular reprogramming events,37 is a topic deserving a deeper and more accurate investigation.
Materials and Methods
Primary mouse dermal fibroblasts expressing GFP were obtained from transgenic mice. Primary human dermal fibroblasts were prepared from a pool of healthy donors. Murine fibroblasts, human fibroblasts, and the mouse myogenic cell line C2C12 in growth were maintained in DMEM high glucose supplemented with 4 mM glutamine, 100 IU/ml penicillin, 100 μg/ml streptomycin, and 10% (v/v) FBS. C2C12 were induced to differentiate into myotubes by replacing 10% FBS with 2% horse serum (HS) in the culture medium. Differentiation was completed in 7–8 days. All cultures were performed at 37°C in a humidified incubator with 5% CO2 and 95% air.
Treatment of fibroblasts with reversine
Reversine was prepared according to the published procedure13 and purity (⩾98%) was checked by HPLC and LC–MS analysis. Mouse or human fibroblasts (8 × 104) were plated in 60 mm dishes in DMEM supplemented with 10% FBS. Fibroblasts were treated with reversine, dissolved in DMSO, at concentrations 0.1–10 μM in 10% FBS DMEM, 18–24 h after seeding. Control cells were incubated with 0.05% DMSO. Treatment was carried out for 4 days without growth medium changes. In some experiments, fibroblasts were treated with reversine or DMSO for 4 days and then shifted to DMEM containing 10–20% (v/v) FBS and grown for 25 days. Cell morphology and proliferation were evaluated with phase-contrast microscope and cells were counted on a hemocytometer.
Cell morphology and growth curve
Mouse fibroblasts (8 × 104) were plated in 60 mm dishes and treated with reversine or DMSO. Cell morphology was examined daily with a phase-contrast microscope (IX50 Olympus) connected with an image analyzer. At each passage, cells were counted on a hemocytometer. Cell viability was determined by trypan blue dye exclusion assay.
Four days after incubation with reversine or DMSO, cytotoxicity was measured using in vitro toxicology assay kit, XTT based,18 (Sigma) according to the manufacturer's protocol. Incubation medium was collected after 3 h and read spectrophotometrically at a wavelength of 450 nm.
Control and treated cells were harvested and fixed in 70% ethanol and kept at 4°C before staining. Fixed cells were resuspended in 1 ml of a solution containing 5 μg/ml propidium iodide (Sigma) in phosphate-buffered saline (PBS) (Gibco Brl), 25 μl RNAse (Sigma) 1 mg/ml, 25 μl of Nonidet P40 (Sigma) 0.15% in water, and stained overnight at 4°C in the dark. Cell analysis was performed on at least 20.000 events for each sample by FACSCalibur System (BD) and DNA profile was analyzed by MODFit 3.0 (Verity Software House).
Fibroblast coculture with C2C12 and myogenic conversion
Murine or human fibroblasts (4 × 104 cells/60 mm dish) were cultured in the presence of 5 μM reversine or DMSO for 4 days, then cells were washed twice with PBS and twice with DMEM containing 10% FBS. C2C12 myoblasts (2 × 105 cells/60 mm dish) were then added to fibroblasts-containing plates. The following day cocultures were shifted in DMEM supplemented with 2% HS. Differentiation was carried out for 8 days. Cells were then fixed with 4% (w/v) paraformaldehyde at room temperature (RT) for 10 min and then permeabilized with 0.1% (w/v) Triton X-100 in PBS for 5 min. Cells were incubated overnight at 4°C with the following primary antibodies: anti-GFP polyclonal antibody (Molecular Probes) at 1 : 200 dilution, anti-MHC (MF20) monoclonal antibody at 1 : 5 dilution, anti-human specific lamin A/C monoclonal antibody (GeneTex) at 1 : 100 dilution. After incubation, cells were washed three times in PBS and incubated with the appropriate FITC- or TRIC-conjugated secondary antibodies 1 h at RT. After washing in PBS, cells were analyzed under a fluorescent microscope (Nikon Eclipse TE 200 microscope equipped with a d × m 1200 Nikon camera). For the coculture experiments of murine fibroblasts with C2C12 cells, the percentages reported of GFP myotubes were calculated by counting the number of GFP-positive myotubes compared to the total myotubes per field. In the case of cocultures with human fibroblasts, we counted the ratio of human nuclei inside or outside the myotubes. The numbers reported are the average of 10 random fields for each experiment. Cell nuclei were counterstained with 4′,6-diamidino-2-phenyindole (DAPI, Sigma). Cocultures of human fibroblasts with C2C12 were also analyzed by RT-PCR with human-specific oligos for Myf5 and MyoD using non-species specific GAPDH as internal standard.
Transwell culture assay with reversine-treated fibroblasts and C2C12 cells
The fibroblast/C2C12 cell transwell culture studies were conducted similarly to the coculture experiments except that fibroblasts treated with reversine (4 days), or untreated, were placed on the bottom of the six-well plate in a thin layer of media and left in the incubator overnight; then a transwell cell culture insert (3.0 μm pore size, Costar, Cambridge, MA, USA) containing differentiating C2C12 was added to the well, and maintained for 5 days, changing the common culture medium every 48 h. After 5 days, the cells were washed with PBS, fixed with 2% PFA and processed for immunofluorescence analysis. Immunostaining was carried out after membrane permeabilization with anti-MHC polyclonal antibody (Sigma) and anti-human nuclei monoclonal antibody (Chemicon, USA). After incubation, cells were washed three times in PBS and incubated with the appropriate FITC- or TRIC-conjugated secondary antibodies 1 h at RT. Cell nuclei were counterstained with DAPI (Sigma). After washing in PBS, cells were analyzed under a fluorescent microscope (Nikon Eclipse TE 200 microscope equipped with a d × m 1200 Nikon camera).
Transdifferentiation to osteoblasts and smooth muscle cells
To induce osteogenic transdifferentiation, reversine or DMSO-treated fibroblasts were cultured in 10% FBS–DMEM supplemented with 0.1 μM dexamethasone, 50 μg/ml ascorbate-2-phosphate, 10 mM β-glycerophosphate. Treatment was carried out for 7 days. Cells were fixed with 2% paraformaldehyde at RT for 10 min and then osteogenic differentiation was assessed with ALP staining (Sigma). Moreover, after reversine or DMSO treatment for 4 days, fibroblasts were transdifferentiated to smooth muscle cells with transforming growth factor-beta 1 (Sigma, 10 ng/ml in DMEM containing 1% FBS for 5 days). Then cells were fixed with 2% paraformaldehyde in PBS for 10 min. Immunostaining was carried out with anti-α-SMA monoclonal antibody (Sigma) at 1 : 100 diluition. After incubation with primary antibody, cells were washed three times in PBS and incubated with FITC-conjugated secondary antibodies 1 h at RT. After washing in PBS, cells were analyzed under a fluorescent microscope (Nikon Eclipse TE 200 microscope equipped with a d × m 1200 Nikon camera). Cell nuclei were counterstained with DAPI (Sigma).
Transplantation of reversine-treated fibroblasts into regenerating skeletal muscle
C57 mice were bred and maintained in the San Raffaele Hospital SPF animal care facility and all experiments were carried out in accordance with European law for animal laboratory experiments. Host muscles were injected with cardiotoxin (50 ng/ml in 10 μl) 24 h before fibroblast transplantation in the TA muscles.39 A Hamilton syringe was used to inject the donor cells (106 in 20 μl PBS total volume for each muscle) into the host TA muscle after the skin incision. At 35 days after cell transplantation, the mice were killed and the muscle processed for immunofluorescence according to the following protocol. Muscle samples from mice after transplantation with reversine-treated and untreated fibroblasts were frozen in liquid nitrogen, cooled isopentane and serial 10 μm thick sections were cut with a Leyca cryostat. Tissue sections were stained with hematoxylin eosin (H&E) or processed for immunofluorescence analysis. Briefly, samples were permeabilized with 0.1% Triton X-100, 0.2% bovine serum albumin (BSA) in PBS for 10 min at RT. Tissue sections were washed three times with 0.2% BSA in PBS, and incubated overnight at 4°C with the following primary antibodies: anti-GFP polyclonal antibody (1 : 200), anti-MHC (MF20) monoclonal antibody (1 : 5), and anti-laminin polyclonal antibody (Sigma) (1 : 100). The number of GFP-positive fibers was calculated in three different experiments, counting the positive fibers per picture field using a microscope equipped with a 10-fold magnification objective.
embryonic stem cells
green fluorescent protein
Alison MR, Poulsom R, Forbes S and Wright NA (2002) An introduction to stem cells. J. Pathol. 197: 419–423.
Blau HM, Brazelton TR and Weimann JM (2001) The evolving concept of a stem cell: entity or function? Cell 105: 829–841.
Wagers AJ and Weissman IL (2004) Plasticity of adult stem cells. Cell 116: 639–648.
Fang TC and Poulsom R (2003) Cell-based therapies for birth defects: a role for adult stem cell plasticity? Birth Defects Res Part C Embryo Today 69: 238–249.
Huard J, Cao B and Qu-Petersen Z (2003) Muscle-derived stem cells: potential for muscle regeneration. Birth Defects Res Part C Embryo Today 69: 230–237.
Reyes M, Dudek A, Jahagirdar B, Koodie L, Marker PH and Verfaille CM (2002) Origin of endothelial progenitors in human postnatal bone marrow. J. Clin. Invest. 109: 337–346.
Minasi MG, Riminucci M, De Angelis L, Borello U, Berarducci B, Innocenzi A, Caprioli A, Sirabella D, Baiocchi M, De Maria R, Boratto R, Jaffredo T, Broccoli V, Bianco P and Cossu G (2002) The meso-angioblast: a multipotent, self-renewing cell that originates from the dorsal aorta and differentiates into most mesodermal tissues. Development 129: 2773–2783.
Bachrach E, Li S, Perez AL, Schienda J, Liadaki K, Volinski J, Flint A, Chamberlain J and Kunkel LM (2004) Systemic delivery of human microdystrophin to regenerating mouse dystrophic muscle by muscle progenitor cells. Proc. Natl. Acad. Sci. USA 101: 3581–3586.
Raff M (2003) Adult stem cell plasticity: fact or artifact? Annu. Rev. Cell. Dev. Biol. 19: 1–22.
Ding S and Schultz PG (2004) A role for chemistry in stem cell biology. Nat. Biotechnol. 22: 833–840.
Rosania GR, Chang YT, Perez O, Sutherlin D, Dong H, Lockhart DJ and Schultz PG (2000) Myoseverin, a microtubule-binding molecule with novel cellular effects. Nat. Biotechnol. 18: 304–308.
Perez OD, Chang YT, Rosania G, Sutherlin D and Schultz PG (2002) Inhibition and reversal of myogenic differentiation by purine-based microtubule assembly inhibitors. Chem. Biol. 9: 475–483.
Chen S, Zhang Q, Wu X, Schultz PG and Ding S (2004) Dedifferentiation of lineage-committed cells by a small molecule. J. Am. Chem. Soc. 126: 410–411.
Katagiri T, Yamaguchi A, Komaki M, Abe E, Takahashi N, Ikeda T, Rosen V, Wozney JM, Fujisawa-Sehara A and Suda T (1994) Bone morphogenetic protein-2 converts the differentiation pathway of C2C12 myoblasts into the osteoblast lineage. J. Cell. Biol. 127: 1755–1766.
Holst D, Luquet S, Kristiansen K and Grimaldi PA (2003) Roles of peroxisome proliferator-activated receptors delta and gamma in myoblast transdifferentiation. Exp. Cell. Res. 288: 168–176.
Fux C, Mitta B, Kramer BP and Fussenegger M (2004) Dual-regulated expression of C/EBP-alpha and BMP-2 enables differential differentiation of C2C12 cells into adipocytes and osteoblasts. Nucleic. Acids Res. 32: e1.
Kumar TK, Jayaraman G, Lee CS, Arunkumar AI, Sivaraman T, Samuel D and Yu C (1997) Snake venom cardiotoxins-structure, dynamics, function and folding. J. Biomol. Struct. Dyn. 15: 431–463.
Roehm NW, Rodgers GH, Hatfield SM and Glasebrook AL (1991) An improved colorimetric assay for cell proliferation and viability utilizing the tetrazolium salt XTT. J. Immunol. Methods 142: 257–265.
Gray NS, Wodicka L, Thunnissen AM, Norman TC, Kwon S, Espinoza FH, Morgan DO, Barnes G, LeClerc S, Meijer L, Kim SH, Lockhart DJ and Schultz PG (1998) Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science 281: 533–538.
Chang YT, Gray NS, Rosania GR, Sutherlin DP, Kwon S, Norman TC, Sarohia R, Leost M, Meijer L and Schultz PG (1999) Synthesis and application of functionally diverse 2, 6, 9-trisubstituted purine libraries as CDK inhibitors. Chem. Biol. 6: 361–375.
Guidotti JE, Bregerie O, Robert A, Debey P, Brechot C and Desdouets C (2003) Liver cell polyploidization: a pivotal role for binuclear hepatocytes. J. Biol. Chem. 278: 19095–19101.
Kuroda K and Tajima S (2004) HSP47 is a useful marker for skin fibroblasts in formalin-fixed, paraffin-embedded tissue specimens. J. Cutan. Pathol. 31: 241–246.
Civin CI, Strauss LC, Brovall C, Fackler MJ, Schwartz JF and Shaper JH (1984) Antigenic analysis of hematopoiesis* III* A hematopoietic progenitor cell surface antigen defined by a monoclonal antibody raised against KG-1a cells. J. Immunol. 133: 157–165.
Lee JY, Qu-Petersen Z, Cao B, Kimura S, Jankowski R, Cummins J, Usas A, Gates C, Robbins P, Wernig A and Huard J (2000) Clonal isolation of muscle-derived cells capable of enhancing muscle regeneration and bone healing. J. Cell. Biol. 150: 1085–1100.
Seale P, Sabourin LA, Girgis-Gabardo A, Mansouri A, Gruss P and Rudnicki MA (2000) Pax7 is required for the specification of myogenic satellite cells. Cell 102: 777–786.
Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S and Marshak DR (1999) Multilineage potential of adult human mesenchymal stem cells. Science 284: 143–147.
Skliris GP, Munot K, Bell SM, Carder PJ, Lane S, Horgan K, Lansdown MR, Parkes AT, Hanby AM, Markham AF and Speirs V (2003) Reduced expression of oestrogen receptor beta in invasive breast cancer and its re-expression using DNA methyl transferase inhibitors in a cell line model. J. Pathol. 201: 213–220.
Milhem M, Mahmud N, Lavelle D, Araki H, DeSimone J, Saunthararajah Y and Hoffman R (2004) Modification of hematopoietic stem cell fate by 5aza 2′deoxycytidine and trichostatin A. Blood 103: 4102–4110.
Kumakura S, Tsutsui TW, Yagisawa J, Barrett JC and Tsutsui T (2005) Reversible conversion of immortal human cells from telomerase-positive to telomerase-negative cells. Cancer Res. 65: 2778–2786.
Dodge JE, Okano M, Dick F, Tsujimoto N, Chen T, Wang S, Ueda Y, Dyson N and Li E (2005) Inactivation of Dnmt3b in mouse embryonic fibroblasts results in DNA hypomethylation, chromosomal instability, and spontaneous immortalization. J. Biol. Chem. 280: 17986–17991.
Ravid K, Lu J, Zimmet JM and Jones MR (2002) Roads to polyploidy: the megakaryocyte example. J. Cell. Physiol. 190: 7–20.
Lattanzi L, Salvatori G, Coletta M, Sonnino C, Cusella De Angelis MG, Gioglio L, Murry CE, Kelly R, Ferrari G, Molinaro M, Crescenzi M, Mavilio F and Cossu G (1998) High efficiency myogenic conversion of human fibroblasts by adenoviral vector-mediated MyoD gene transfer. An alternative strategy for ex vivo gene therapy of primary myopathies. J. Clin. Invest. 101: 2119–2128.
Odelberg SJ, Kollhoff A and Keating MT (2000) Dedifferentiation of mammalian myotubes induced by msx1. Cell 103: 1099–1109.
McGann CJ, Odelberg SJ and Keating MT (2001) Mammalian myotube dedifferentiation induced by newt regeneration extract. Proc. Natl. Acad. Sci. USA 98: 13699–13704.
Perreira M, Jiang JK, Klutz AM, Gao ZG, Shainberg A, Lu C, Thomas CJ and Jacobson KA (2005) Reversine and its 2-substituted adenine derivatives as potent and selective A3 adenosine receptor antagonists. J. Med. Chem. 48: 4910–4918.
Lee JH, Hart SR and Skalnik DG (2004) Histone deacetylase activity is required for embryonic stem cell differentiation. Genesis 38: 32–38.
Blelloch RH, Hochedlinger K, Yamada Y, Brennan C, Kim M, Mintz B, Chin L and Jaenisch R (2004) Nuclear cloning of embryonal carcinoma cells. Proc. Natl. Acad. Sci. USA 101: 13985–13990.
Chomczynski P and Sacchi N (1987) Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162: 156–159.
Ferrari G, Cusella-De Angelis G, Coletta M, Paolucci E, Stornaiuolo A, Cossu G and Mavilio F (1998) Muscle regeneration by bone marrow-derived myogenic progenitors. Science 279: 1528–1530.
The authors would like to thank students Francesca Colazzo and Alessandra Colombini for their valuable help in some experiments. This study was supported by PRIN (2004), AFM, MDA, Telethon, Duchenne Parent Project, European Community, Cariplo Foundation, and Italian Ministries of Health and Research.
Edited by G Melino
About this article
Cite this article
Anastasia, L., Sampaolesi, M., Papini, N. et al. Reversine-treated fibroblasts acquire myogenic competence in vitro and in regenerating skeletal muscle. Cell Death Differ 13, 2042–2051 (2006). https://doi.org/10.1038/sj.cdd.4401958
This article is cited by
Indian Journal of Clinical Biochemistry (2020)
Relation of AURKB over-expression to low survival rate in BCRA and reversine-modulated aurora B kinase in breast cancer cell lines
Cancer Cell International (2019)
Basic Research in Cardiology (2017)
Clinical Epigenetics (2016)
Molecular and Cellular Biochemistry (2016)